Gregg W. Stone
Devoted Researcher
Dr. Gregg W. Stone (USA) is the Director of Academic Affairs for Mount Sinai Heart Health System and holds professorships in Medicine (Cardiology) and Population Health Sciences at the Icahn School of Medicine at Mount Sinai. A leading clinical researcher, he has led numerous global studies and served as the principal investigator for over 140 multicenter randomized trials, including TAXUS IV, TAXUS V, PROSPECT, EXCEL, and COAPT. With over 3,000 publications, his expertise spans interventional therapies for acute coronary syndromes, drug-eluting stents, antiplatelet therapies, and transcatheter mitral valve procedures. He is the person with the most published articles in The New England Journal of Medicine (NEJM). He received the “Master of the Masters” Award at TCTAP in 2020 for his significant contributions to interventional cardiology.
The last count I think I’ve got about 18 to 20 papers that you have published as first or senior author in the NEJM. It’s clear that your contribution goes beyond interventional cardiology and is a major achievement in medicine as well. (Alan C. Yeung) Gregg has made many contributions to interventional cardiology. But the one that stands out, of course, is his contributions in clinical trials of the design, the execution of those trials that have made major impact on our specialty. (Spencer B. King III) His fields of interest have been broad and include all of cardiovascular disease, both from those patients that have chronic angina to the treatment of complex coronary artery disease, to new technologies such as bio-vascular scaffolds, to the evaluation and treatment of patients with mitral regurgitation such as the recent COAPT trial. (David R. Holmes) Over the past two decades, I truly believe that Gregg W. Stone has been among the premier clinical trialists in evidence-based medicine and interventional cardiology, and he’s made enormous contributions to the field that have been truly practice-changing. (Martin Bert Leon)
Gregg is a master of hard work. He is constantly working hard to improve himself and science by taking on new challenges and thinking through even simple questions to find a different or better way to approach a challenge. (Akiko Maehara) You have always been adamant in the research of these fields. You were looking to find answers, scientifically based answers, too many open questions in coronary disease and of course in structural disease. (Eberhard Grube)
Dr. Gregg W. Stone (USA) is the Director of Academic Affairs for Mount Sinai Heart Health System and holds professorships in Medicine (Cardiology) and Population Health Sciences at the Icahn School of Medicine at Mount Sinai. A leading clinical researcher, he has led numerous global studies and served as the principal investigator for over 140 multicenter randomized trials, including TAXUS IV, TAXUS V, PROSPECT, EXCEL, and COAPT. With over 3,000 publications, his expertise spans interventional therapies for acute coronary syndromes, drug-eluting stents, antiplatelet therapies, and transcatheter mitral valve procedures. He is the person with the most published articles in The New England Journal of Medicine (NEJM). He received the “Master of the Masters” Award at TCTAP in 2020 for his significant contributions to interventional cardiology.
The last count I think I’ve got about 18 to 20 papers that you have published as first or senior author in the NEJM. It’s clear that your contribution goes beyond interventional cardiology and is a major achievement in medicine as well. (Alan C. Yeung) Gregg has made many contributions to interventional cardiology. But the one that stands out, of course, is his contributions in clinical trials of the design, the execution of those trials that have made major impact on our specialty. (Spencer B. King III) His fields of interest have been broad and include all of cardiovascular disease, both from those patients that have chronic angina to the treatment of complex coronary artery disease, to new technologies such as bio-vascular scaffolds, to the evaluation and treatment of patients with mitral regurgitation such as the recent COAPT trial. (David R. Holmes) Over the past two decades, I truly believe that Gregg W. Stone has been among the premier clinical trialists in evidence-based medicine and interventional cardiology, and he’s made enormous contributions to the field that have been truly practice-changing. (Martin Bert Leon)
Gregg is a master of hard work. He is constantly working hard to improve himself and science by taking on new challenges and thinking through even simple questions to find a different or better way to approach a challenge. (Akiko Maehara) You have always been adamant in the research of these fields. You were looking to find answers, scientifically based answers, too many open questions in coronary disease and of course in structural disease. (Eberhard Grube)